RT Journal Article
SR Electronic
T1 Prevalence of amyloid blood clots in COVID-19 plasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.28.20163543
DO 10.1101/2020.07.28.20163543
A1 Etheresia Pretorius
A1 Chantelle Venter
A1 Gert Jacobus Laubscher
A1 Petrus Johannes Lourens
A1 Janami Steenkamp
A1 Douglas B Kell
YR 2020
UL http://medrxiv.org/content/early/2020/07/29/2020.07.28.20163543.abstract
AB The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 virus in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological test that indicated whether the individual was infected or not would be highly desirable. Coagulaopathies are a common accompaniment to COVID-19, especially micro-clots within the lungs. We show here that microclots can be detected in the native plasma of COVID-19 patient, and in particular that such clots are amyloid in nature as judged by a standard fluorogenic stain. This provides a rapid and convenient test (P<0.0001), and suggests that the early detection and prevention of such clotting could have an important role in therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementWe thank the Medical Research Council of South Africa (MRC) (Self-Initiated Research Program: A0X331) for supporting this collaboration. DBK thanks the Novo Nordisk Foundation for funding (grant NNF10CC1016517).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for blood collection and analysis of the patients with COVID-19 and healthy individuals, was given by the Health Research Ethics Committee (HREC) of Stellenbosch University (reference number: 9521).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is available at: https://1drv.ms/u/s!AgoCOmY3bkKHirZOu5YKPlq1x5f1AQ?e=xmWGKm https://1drv.ms/u/s!AgoCOmY3bkKHirZOu5YKPlq1x5f1AQ?e=xmWGKm